Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 17, 2010 Brian Orelli	$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
The Motley Fool December 15, 2010 Brian Orelli	Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool June 21, 2007 Brian Orelli	Dumpster Diving in Pfizer's Trash Investors are probably overreacting to Pfizer's decision, but only time -- and clinical trials -- will tell.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool December 3, 2010 Brian Orelli	Merck Smartens Up The acquisition of SmartCells looks like an intelligent move.
Bio-IT World March 2006 Kevin Davies	Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool September 28, 2006 Brian Lawler	Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool August 31, 2009 Brian Orelli	Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it..
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool May 1, 2007 Brian Lawler	Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note.
The Motley Fool June 25, 2010 Brian Orelli	Diversification Times 50,000 Gilead Sciences diversifies any way it can.
The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
AskMen.com Richard Stevens	Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Rheumatoid Arthritis: JAKing Down Inflammation In the race to market the first oral drug to compete with high-priced injectables for rheumatoid arthritis, Pfizer's tasocitinib has the home-stretch lead over Rigel, Vertex, and Incyte.
The Motley Fool April 26, 2007 Tom Taulli	Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth.
The Motley Fool July 18, 2005 Karl Thiel	Stocks That Make You Breathe Easier Allergies and asthma are big markets that several firms aim to tackle. Investors, take note.
The Motley Fool June 21, 2004 Brian Gorman	Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings.
The Motley Fool June 4, 2008 Brian Orelli	Expanding Possibilities Fail to Expand Rigel's Stock Price Rigel gets positive data on a second indication for its lead drug, R788.
Fast Company December 2009 Erica Westly	The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
Chemistry World October 15, 2013 Dinsa Sachan	Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed.